Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Stock Climbs 13 Percent on New Patent Win

NEW YORK (GenomeWeb News) – Shares in Accelr8 were up 13.17 percent, or $.27, at $2.32 in mid-afternoon trading after the company said it won a US patent that covers devices that use its OptiChem surface chemistry, including those for patient specimen collection and analytical products.
 
Accel8 said U.S. Patent 7,067,194 also covers coating variations not specifically included in prior patents.
 
Accelr8 previously licensed certain OptiChem applications to other companies in the biomedical industry. The firm is now developing its BACcelr8r rapid bacterial diagnostic system that will use OptiChem in its single-use analytical cassette.
 
In addition, Accelr8 said it plans to develop related disposable products for handling patient specimens prior to analysis.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.